> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Collaborative Review of Scientific Pharmacogenetic Info
- URL: https://www.fdaweb.com/collaborative-review-of-scientific-pharmacogenetic-info/
- Published: 2020-02-20T12:00:00.000Z
- Updated: 2026-09-14T16:03:47.000Z
- Author: David McFarland
- Tags: Drugs, Devices, #legacy-id-D5146134

CDRH and CDER say they are collaborating on an effort to provide FDA’s view of the state of the current science in pharmacogenetics. They are launching a Web-based [resource](https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations?ref=fdaweb.com) that includes a table describing “some of the gene-drug interactions for which the agency believes there is sufficient scientific evidence to support the described associations between certain genetic variants, or genetic variant-inferred phenotypes, and altered drug metabolism, and in certain cases, differential therapeutic effects, including differences in risks of adverse events.”

The table includes established gene-drug interactions that appear in FDA-approved drug labeling as well as some additional gene-drug interactions that are consistent with the current FDA labeling and for which there is sufficient scientific evidence based on published literature.

An agency online [statement](https://www.fda.gov/news-events/press-announcements/fda-announces-collaborative-review-scientific-evidence-support-associations-between-genetic?ref=fdaweb.com) says FDA is exploring additional approaches for evaluating the evidence underlying gene-drug associations, such as participating in a community-based collaborative approach to the ongoing evolution of the evolving science.